Hoos A. Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations. Nat Rev Drug Discov. 2016;15(4):235–47.

Article  CAS  PubMed  Google Scholar 

Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol. 2023;20(6):359–71.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang Y, Zhang H, Liu C, Wang Z, Wu W, Zhang N, et al. Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts. J Hematol Oncol. 2022;15(1):111.

Article  PubMed  PubMed Central  Google Scholar 

Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, et al. Five-year survival with combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2019;381(16):1535–46.

Article  CAS  PubMed  Google Scholar 

Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol. 2019;30(4):582–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Garon EB, Hellmann MD, Rizvi NA, Carcereny E, Leighl NB, Ahn MJ, et al. Five-year overall survival for patients with Advanced non–small-cell lung Cancer treated with Pembrolizumab: results from the phase I KEYNOTE-001 study. J Clin Oncol. 2019;37(28):2518–27.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jia Q, Wang A, Yuan Y, Zhu B, Long H. Heterogeneity of the tumor immune microenvironment and its clinical relevance. Exp Hematol Oncol. 2022;11(1):24.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yuan Y, Li H, Pu W, Chen L, Guo D, Jiang H, et al. Cancer metabolism and tumor microenvironment: fostering each other? Sci China Life Sci. 2022;65(2):236–79.

Article  CAS  PubMed  Google Scholar 

Junttila MR, de Sauvage FJ. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature. 2013;501(7467):346–54.

Article  CAS  PubMed  Google Scholar 

Gajewski TF. The next hurdle in Cancer Immunotherapy: overcoming the Non-t-cell-inflamed Tumor Microenvironment. Semin Oncol. 2015;42(4):663–71.

Article  PubMed  PubMed Central  Google Scholar 

Kim SJ, Khadka D, Seo JH. Interplay between Solid Tumors and Tumor Microenvironment. Front Immunol. 2022;13:882718.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Taddei ML, Giannoni E, Comito G, Chiarugi P. Microenvironment and tumor cell plasticity: an easy way out. Cancer Lett. 2013;341(1):80–96.

Article  CAS  PubMed  Google Scholar 

Hegde PS, Chen DS. Top 10 challenges in Cancer Immunotherapy. Immunity. 2020;52(1):17–35.

Article  CAS  PubMed  Google Scholar 

Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 2019;18(3):197–218.

Article  CAS  PubMed  Google Scholar 

Galon J, Angell HK, Bedognetti D, Marincola FM. The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity. 2013;39(1):11–26.

Article  CAS  PubMed  Google Scholar 

Mlecnik B, Bindea G, Angell HK, Maby P, Angelova M, Tougeron D, et al. Integrative analyses of Colorectal Cancer Show Immunoscore is a stronger predictor of patient survival than microsatellite instability. Immunity. 2016;44(3):698–711.

Article  CAS  PubMed  Google Scholar 

Tang H, Wang Y, Chlewicki LK, Zhang Y, Guo J, Liang W, et al. Facilitating T cell infiltration in Tumor Microenvironment overcomes resistance to PD-L1 blockade. Cancer Cell. 2016;30(3):500.

Article  CAS  PubMed  Google Scholar 

Pages F, Mlecnik B, Marliot F, Bindea G, Ou FS, Bifulco C, et al. International validation of the consensus immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018;391(10135):2128–39.

Article  PubMed  Google Scholar 

Angell H, Galon J. From the immune contexture to the immunoscore: the role of prognostic and predictive immune markers in cancer. Curr Opin Immunol. 2013;25(2):261–7.

Article  CAS  PubMed  Google Scholar 

Loibl S, Schneeweiss A, Huober J, Braun M, Rey J, Blohmer JU, et al. Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response. Ann Oncol. 2022;33(11):1149–58.

Article  CAS  PubMed  Google Scholar 

Hegde PS, Karanikas V, Evers S. The where, the when, and the How of Immune Monitoring for Cancer immunotherapies in the era of checkpoint inhibition. Clin Cancer Res. 2016;22(8):1865–74.

Article  CAS  PubMed  Google Scholar 

Zhang J, Huang D, Saw PE, Song E. Turning cold tumors hot: from molecular mechanisms to clinical applications. Trends Immunol. 2022;43(7):523–45.

Article  CAS  PubMed  Google Scholar 

Adams S, Dieras V, Barrios CH, Winer EP, Schneeweiss A, Iwata H, et al. Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer. Ann Oncol. 2020;31(5):582–9.

Article  CAS  PubMed  Google Scholar 

Sweis RF, Spranger S, Bao R, Paner GP, Stadler WM, Steinberg G, et al. Molecular drivers of the Non-t-cell-inflamed Tumor Microenvironment in urothelial bladder Cancer. Cancer Immunol Res. 2016;4(7):563–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541(7637):321–30.

Article  CAS  PubMed  Google Scholar 

Castiglioni A, Yang Y, Williams K, Gogineni A, Lane RS, Wang AW, et al. Combined PD-L1/TGFbeta blockade allows expansion and differentiation of stem cell-like CD8 T cells in immune excluded tumors. Nat Commun. 2023;14(1):4703.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Voorwerk L, Slagter M, Horlings HM, Sikorska K, van de Vijver KK, de Maaker M, et al. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. Nat Med. 2019;25(6):920–8.

Article  CAS  PubMed  Google Scholar 

Desbois M, Wang Y. Cancer-associated fibroblasts: Key players in shaping the tumor immune microenvironment. Immunol Rev. 2021;302(1):241–58.

Article  CAS  PubMed  Google Scholar 

Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Science. 2015;348(6230):74–80.

Article  CAS  PubMed  Google Scholar 

Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415–21.